Also, several properly proven adverse prognostic markers, such as U-CLL, ATM aberrations or NOTCH1/BIRC3 mutations, dropped their adverse impact in people dealt with with VO. The sole variable that remained predictive of a shorter progression-free survival During this cohort of patients was TP53 aberrations.112 Eventually, the alternative BTK inhib